Tobramycin (Drops) Instructions for Use
ATC Code
S01AA12 (Tobramycin)
Active Substance
Tobramycin (Rec.INN registered by WHO)
Clinical-Pharmacological Group
Antibiotic for topical use in ophthalmology
Pharmacotherapeutic Group
Antibiotic-aminoglycoside
Pharmacological Action
A broad-spectrum antibiotic from the aminoglycoside group. In low concentrations, it acts bacteriostatically (blocks the 30S ribosomal subunit and disrupts protein synthesis), and in higher concentrations, it acts bactericidally (disrupts the function of cytoplasmic membranes, causing the death of the microbial cell).
Highly active againstStaphylococcus spp. (including Staphylococcus aureus, Staphylococcus epidermidis /coagulase-negative and coagulase-positive/, as well as strains resistant to penicillin); Streptococcus spp. (including α-β-hemolytic species, some non-hemolytic species, Streptococcus pneumoniae); Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis (indole-negative) and indole-positive species of Proteus spp., Haemophilus influenzae, Haemophilus aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus (Herellea vaginicola), some species of Neisseria spp. (including Neisseria gonorrhoeae).
Pharmacokinetics
With topical application, systemic absorption is low.
Indications
Blepharitis; conjunctivitis; keratoconjunctivitis; blepharoconjunctivitis; keratitis; iridocyclitis; prevention of postoperative complications in ophthalmology.
ICD codes
| ICD-10 code | Indication |
| H01.0 | Blepharitis |
| H10.2 | Other acute conjunctivitis |
| H10.4 | Chronic conjunctivitis |
| H10.5 | Blepharoconjunctivitis |
| H16 | Keratitis |
| H16.2 | Keratoconjunctivitis (including that caused by external influence) |
| H20.0 | Acute and subacute iridocyclitis (anterior uveitis) |
| H20.1 | Chronic iridocyclitis |
| Z29.2 | Other prophylactic chemotherapy (administration of antibiotics for prophylactic purposes) |
| ICD-11 code | Indication |
| 9A01.3 | Infectious blepharitis |
| 9A02.Z | Inflammatory disorders of eyelid, unspecified |
| 9A60.4 | Blepharoconjunctivitis |
| 9A60.5 | Vernal keratoconjunctivitis |
| 9A60.Z | Conjunctivitis, unspecified |
| 9A71 | Infectious keratitis |
| 9A73 | Exposure keratitis |
| 9A74 | Neurotrophic keratitis |
| 9A7Y | Other specified diseases of cornea |
| 9A7Z | Diseases of the cornea, unspecified |
| 9A96.Y | Other specified anterior uveitis |
| 9A96.Z | Anterior uveitis, unspecified |
| QC05.Y | Other specified prophylactic measures |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
For mild to moderate eye infections, instill one to two drops into the affected eye(s) every four hours.
For severe infections, increase the frequency to one to two dropsevery hour until improvement occurs, then reduce the frequency.
Do not use the solution if it is discolored or contains particles.
Wash hands thoroughly before use.
Avoid touching the dropper tip to any surface to prevent contamination.
For postoperative prophylaxis, follow the specific regimen prescribed by the surgeon, typically beginning 24 hours after surgery.
The usual duration of therapy is seven to ten days.
Do not discontinue therapy prematurely, even if symptoms improve.
If no improvement is observed after one week of treatment, re-evaluate the patient.
Contact lenses must be removed before instillation of the drops.
Wait at least 15 minutes after instillation before reinserting contact lenses.
Adverse Reactions
Allergic reactions itching and swelling of the eyelids, conjunctival hyperemia, lacrimation. Burning sensation and foreign body sensation in the eye may occur.
Contraindications
Hypersensitivity to tobramycin, children under 1 year of age, breastfeeding period.
Use in Pregnancy and Lactation
There is insufficient experience with the use of the drug during pregnancy and breastfeeding. Use during pregnancy is not recommended. Use during breastfeeding is contraindicated.
Pediatric Use
Contraindicated for use in children under 1 year of age.
Geriatric Use
Use with caution in elderly patients to avoid the risk of exacerbation of chronic diseases.
Special Precautions
Cross-hypersensitivity to other aminoglycosides may develop, and it should be considered that patients who have developed hypersensitivity to topical tobramycin may also be sensitive to other topical and/or systemic aminoglycosides.
Serious adverse reactions, including neurotoxicity, ototoxicity, and nephrotoxicity, may occur in patients receiving systemic tobramycin therapy. Use caution when combining topical Tobramycin with systemic aminoglycosides.
Use with caution in patients with suspected or confirmed neuromuscular disorders, such as Parkinson’s disease or myasthenia gravis. Aminoglycosides may exacerbate muscle weakness due to a potential effect on neuromuscular conduction.
Long-term use of the antibiotic may lead to overgrowth of non-susceptible microorganisms, including fungi. If superinfection occurs, appropriate therapy should be initiated.
Patients who experience temporary blurred vision after using tobramycin are not recommended to engage in activities requiring increased attention and quick reactions until it is restored.
Drug Interactions
With simultaneous use of topical tobramycin with systemic aminoglycoside antibiotics, systemic side effects may be enhanced.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Eye drops 0.3%: 5 ml dropper bottle
Marketing Authorization Holder
Sintez PJSC (Russia)
Dosage Form
| Tobramycin | Eye drops 0.3%: 5 ml dropper bottle |
Dosage Form, Packaging, and Composition
Eye drops as a transparent or slightly opalescent solution from colorless to light yellow.
| 1 ml | |
| Tobramycin | 3 mg |
Excipients : benzalkonium chloride, disodium edetate dihydrate (disodium salt of ethylenediaminetetraacetic acid dihydrate (Trilon B)), sodium chloride, hypromellose, water for injection.
5 ml – plastic dropper bottles (1) – cardboard packs.
Eye drops 0.3%: bottle 10 ml 1 pc.
Marketing Authorization Holder
Medisorb, JSC (Russia)
Dosage Form
| Tobramycin Medisorb | Eye drops 0.3%: bottle 10 ml 1 pc. |
Dosage Form, Packaging, and Composition
Eye drops as a transparent, colorless or slightly brownish liquid.
| 1 ml | |
| Tobramycin | 3 mg |
Excipients : mannitol, boric acid, trometamol, sodium hydroxide and/or sulfuric acid to adjust pH to 6.0-8.0, purified water.
10 ml – bottles (1) – cardboard packs.
